Objectives: Androgenetic Alopecia (AGA) is a chronic miniaturization of the scalp hair follicle it affects 50% of men and 13% of premenopausal women, though it is increased in premenopausal women.

Introduction: AGA is a complex condition with no one-size-fits-all treatment approach. However, there are a variety of effective treatments available, both traditional and new

Materials / method: PowerPoint slides or other presentation software
Pictures or diagrams of AGA hair loss patterns

Results: I will be discussing the new updates of AGA from traditional and known therapies such as, Topical Minoxidil, DHT Blockers, finasteride and dutasteride to new techniques that showed promising and effective results like oral minoxidil and regenerative medicine AKA exosomes and how patients are responding to the new treatments.

Conclusion: This presentation is intended for healthcare professionals who are interested in learning about the latest updates on AGA treatments and how patients should work with their healthcare provider to choose the best treatment plan for their individual needs.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: * Learn the mechanism of action of minoxidil

* Learn the limitations of minoxidil response

* Learn on botanical adjuvants for minoxidil therapy

Introduction: Minoxidil is the only US FDA approved topical drug for the treatment of androgenetic alopecia. Minoxidil is effective in hair re-growth in 30-40% of patients and 50% of males. To exert its hair growing effect, minoxidil must be sulfonated in the scalp by the minoxidil sulfotransferase enzyme (SULT1A1). Low scalp SULT1A1 correlates with lack of minoxidil response; thus, supplementing the scalp SULT1A1 with naturally occurring minoxidil sulfotransferase enzymes could potentially improve treatment outcomes in androgenetic alopecia patients.

Materials / method: To determine whether botanical extracts contain minoxidil sulfotransferase enzyme activity, different types of extracts were reacted with the test solution [Minoxidil Response Test (MRT) solution A total of 10 different plants were tested. The following plants were selected based on high flavonoid content as the final step in flavonoid synthesis requires sulfation: Broccoli Powder, Spinach Powder, Kale, Grape Seed, Olive Leaf Powder, Cabbage Powder, Cherry Juice, Red Cabbage, Cauliflower Power and Matcha Powder.

Results: From the 10 common botanical extracts we studied, 7 exhibited significant activity toward minoxidil as a substrate. The botanical extracts with the highest OD at the lowest concentration correlated to an increased potency of the enzyme sulfotransferase. Three botanical extracts in particular, spinach powder, matcha powder, and broccoli powder, displayed significant activity at 2uL.

Conclusion: Minoxidil, a potent vasodilator has proven to display therapeutic properties in terms of its effects on stimulating hair follicles. The enzyme, sulfotransferase is key to the drugs mechanism of action, as the drug needs to be converted to its sulfated form to carry out its mechanism of action. The aim of our study was to assess the potential of botanical sulfotransferases in sulfating the xenobiotic minoxidil. The common botanical extracts studied included broccoli, spinach, kale, grape seed, olive leaf, cabbage, cherry juice, red cabbage, cauliflower, and matcha.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: Hair growth options has been used predominantly in the medical fields of musculoskeletal disorders. In recent years however, there has been ongoing research of the use of PRP in a range of other indications including hair loss

Introduction: In recent years however, there has been ongoing research of the use of PRP in a range of other indications including hair loss

Materials / method: Scientific evidence from peer-reviewed studies and the authors own experience were collated to present evidence for the effectiveness of PRP for hair loss in men and women and other hair disorders.

Results: There is substantial evidence on the effectiveness of PRP in treatment of hair loss. Combination strategies with energy-based devices, hair transplantation, nutraceuticals yield synergistic results. Protocol recommendations and long-term maintenance options are discussed.

Conclusion: : PRP is a safe and effective method for treatment of hair loss.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): Calecim, Emma, Kimera

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): Calecim, Emma, Kimera

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Calecim, Emma, Kimera

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Toskanimed

Objectives: To review the newest treatments for alopecia areata, including JAK inhibitors (baricitinib, ritlecitinib, deuruxolitinib), the combination of imiquimod and diphencyprone, etrasimod, dupilumab, topical coacillium, among others.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: 1.Each treatment option comes with its own risks and benefits with varying costs and side effect profiles that are important to consider when initiating therapy.
2. In this lecture I will discuss treatment options like FDA-approved therapies which include topical minoxidil and oral finasteride, often used as first line treatments.However, a variety of off-label options exist including hormone therapy, supplements, low level laser light therapy, platelet rich plasma injections, microneedling, bone marrow derived conditioned media, exosomes, and hair transplantation to consider

Introduction: Androgenetic alopecia (AGA) is the most common form of non-scarring hair loss, and is mediated by 5 alpha-reductase and dihydrotestosterone (DHT). The underlying mechanism involves androgen-sensitive hair follicles which undergo miniaturization via progressive shortening of successive anagen cycles. This leads to the characteristic receding frontal hairline in men and diffuse hair thinning in women. AGA may be distressing and have a negative impact on an affected individual’s quality of life. A variety of medical, surgical, and nutraceutical treatment options are available in the market to slo

Materials / method: A literature search was conducted using electronic databases (Medline, Pubmed, Embase, CINAHL, EBSCO) and textbooks, in addition to the authors’ clinical experience in treating androgenetic alopecia, and the findings are presented here.

Results: AGA-related hair thinning begins between 12-40 years of age in individuals with a genetic predisposition. FDA-approved therapies include topical minoxidil and oral finasteride which are often used as first line treatments. However, a variety of off-label options exist including low level laser light therapy, platelet rich plasma injections, and hair transplantation all of which may be considered as alternative treatments in the appropriate patients.

Conclusion: AGA affects approximately 80% of men and 50% of women with a multifactorial etiology and polygenic inheritance. Despite its high prevalence, AGA remains a challenging condition to treat as approved treatment options are limited and many require high rates of compliance. Each treatment option comes with its own risks and benefits with varying costs and side effect profiles that are important to consider when initiating therapy.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability